Everolimus Granules – Available as Nanoparticles with 2.68% & 5% Strengths.
- MKPPL is the first to come up with pellet based approach for immune suppressants.
- Facilitates direct filling into capsules and can be easily employed in tableting. Nano particles can be effectively used for manufacturing of ointments (Tacrolimus) and solutions (Everolimus).
- MKPPL pellet advantages includes using a micro emulsion technology. No cyclization of the drug, hence less delta lactones formation.
- Coated pellets, hence the formulator does not require a contained facility for finished formulation.
- Offer complete technical package for registrations in all regulated/semi regulated markets.
Share
Additional information
| Percentage | 2.68%, 5% |
|---|---|
| Quality Standard | USP43 |
| Documentation Available: | DMF in CTD Format |
| Routes of administration | Oral |
| Forms of PFI | Granules (for Tablets) |
| Target Formulations | Capsules, Suspension, Tablets |
